ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting

    IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts

    Kunihiko Umekita1, Shunichi Miyauchi1, Kazuyoshi Kubo1, Kazumi Umeki1, Hajime Nomura1, Mao Komura1, Koushou Iwao1, Ichiro Takajo1, Yasuhiro Nagatomo1, Toshihiko Hidaka2 and Akihiko Okayama1, 1Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, 2Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan

    Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
  • Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting

    Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis

    Brian Sauer1, Chia-Chen Teng2, Jianwei Leng3, Ted R. Mikuls4, Jeffrey R. Curtis5, Bradley S. Stolshek6, Derek Tang6 and Grant W. Cannon7, 1IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 2HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 3Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 4University of Nebraska Medical Center, Omaha, NE, 5University of Alabama at Birmingham, Birmingham, AL, 6Amgen, Inc., Thousand Oaks, CA, 7Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
  • Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting

    Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital

    Juan María Blanco-Madrigal1, Maria Luz Garcia Vivar1, Catalina Gomez Arango1, Olaia Fernández Berrizbeitia1, Clara Perez Velasquez1, Ignacio Torre Salaberri2, Jose Francisco Garcia Llorente3, Eva Galindez-Agirregoikoa4, Esther Ruiz Lucea1 and Iñigo Gorostiza5, 1Rheumatology, Basurto University Hospital, Bilbao, Spain, 2Rheumaytology, Basurto University Hospital, Bilbao, Spain, 3Rheumatology, Basurto University Hospital., Bilbao, Spain, 4Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, 5Research Department, BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain

    Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…
  • Abstract Number: 2546 • 2015 ACR/ARHP Annual Meeting

    Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis

    Chrong-Reen Wang1, Jia-Shiou Peng2, Shih-Yao Chen3, Chao-Liang Wu4 and Ai-Li Shiau5, 1Rheum/Immun Sec/Int Med Dept, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, 2Institute of Basic Medical Sciences, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, 3Internal Medicine, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, 4Biochemistry and Molecular Biology, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, 5Microbiology and Immunology, College of Medicine, National Cheng Kung University, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan

    Background/Purpose: Synovial fibroblasts (SF) with aberrant expression of microRNAs (miRNA) are critical pathogenic regulators of rheumatoid joint, and studies examining the effect of overexpressing or…
  • Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation

    Mandar Bawadekar1, Annette Gendron-Fitzpatrick2, Thomas F. Warner3, Lennart K.A. Lundblad4, Paul Thompson5 and Miriam A. Shelef1,6, 1Medicine, University of Wisconsin, Madison, WI, 2Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, 3Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, 4Medicine, The University of Vermont, Burlington, VT, 5University of Massachusetts, Worcester, MA, 6Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI

    Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
  • Abstract Number: 2564 • 2015 ACR/ARHP Annual Meeting

    Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis

    Jackeline Araujo, Cullen Lilley and Kimberlee Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA

    Background/Purpose: The orphan nuclear receptor 4A2 (NR4A2 / NURR1) is emerging as a critical transcription factor in chronic inflammatory joint diseases. We have demonstrated elevated…
  • Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting

    The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response

    Burkhard Leeb1,2, Raimund Lunzer3, Peter Fasching4, Manfred Herold5, O. Zamani6, Winfried Graninger7 and OPTIMISE trial Investigators, 12nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, 2Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, 3Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, 4Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, 5Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, 6Rheumazentrum Favoriten, Wien, Austria, 7Rheumatology and Immunology, Medical University of Graz, Graz, Austria

    Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
  • Abstract Number: 2566 • 2015 ACR/ARHP Annual Meeting

    Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis

    Tomer Bashi1, Miri Blank1, Jasna Omersel2, Alexander Volkov3, Iris Barshack3 and Yehuda Shoenfeld1, 1Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, 2Faculty of pharmacy, University of Ljublijana, Ljublijana, Slovenia, 3Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel

    Background/Purpose: Treatment with helminthes and ova from helminthes, improved clinical findings of several autoimmune diseases in patients and in animal models. We aimed to decipher…
  • Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting

    Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort

    Jeffrey A. Sparks1, Shun-Chiao Chang2, Kevin D. Deane3, Ryan W. Gan4, Kristen Demoruelle3, Marie L. Feser3, LauraKay Moss3, Jane H. Buckner5, Richard M. Keating6, Karen H. Costenbader7, Peter K. Gregersen8, Michael H. Weisman9, Ted R. Mikuls10, James R. O'Dell10, V. Michael Holers3, Jill M. Norris4 and Elizabeth W. Karlson2, 1Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Epidemiology, Colorado School of Public Health, Aurora, CO, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Division of Rheumatology, Scripps Health, La Jolla, CA, 7Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 8Feinstein Insititute for Medical Research, Manhasset, NY, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
  • Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting

    Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice

    Richard Bell1, Ronald Wood2, Joe Chakkalakal3, Christopher T. Ritchlin4, Edward Schwarz5 and Homaira Rahimi6, 1Pathology, University of Rochester, Rochester, NY, 2University of Rochester, Rochester, NY, 3Orthopaedics, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Orthopedeatrics, University of Rochester, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
  • Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting

    Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis

    Jing Yao Leong1,2, Raymond Ong Jr.3, Juntao Li4, Theodorus van den Broek5, Roberto Spreafico4, Maura Rossetti1 and Salvatore Albani1,2, 1SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, 2Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, 3Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 4SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 5Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA

    Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…
  • Abstract Number: 2704 • 2015 ACR/ARHP Annual Meeting

    Neutrophil-Derived Lactoferrin Regulates the Activity of NFAT5 in Rheumatoid Arthritis Synovial Fibroblasts Via Toll-like Receptor 4

    Kunihiko Umekita, Shunichi Miyauchi, Kazuyoshi Kubo, Hajime Nomura, Kazumi Umeki, Koushou Iwao, Mao Komura and Akihiko Okayama, Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan

    Background/Purpose: Damage-associated molecular patterns (DAMPs) are proposed to drive aberrant stimulation of Toll-like receptors (TLRs) in the rheumatoid arthritis (RA) joints resulting in increased expression…
  • Abstract Number: 1586 • 2015 ACR/ARHP Annual Meeting

    Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment

    Elisa Gremese1, Maria Rita Gigante1, Barbara Tolusso1, Anna Laura Fedele1, Silvia Canestri1, Barbara Aquilanti2, Clara Di Mario1, Luca Petricca1, Stefano Alivernini1 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Dietology Service, Association Columbus, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Obesity is recognized as a systemic, low-grade inflammatory state and the adipose tissue as an endocrine organ releasing pro-inflammatory cytokines. On the other hand,…
  • Abstract Number: 2705 • 2015 ACR/ARHP Annual Meeting

    AAA-Atpase p97-HDAC6 Controlled Poly-Ubiquitin Turnover Regulates Apoptotic and Autophagy-Associated Cell Death in Arthritis

    Masaru Kato1, Kerstin Klein2, Caroline Ospelt2, Christoph Kolling3, Michihito Kono1, Shinsuke Yasuda1, Renate E. Gay4, Steffen Gay5 and Tatsuya Atsumi1, 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Schulthess Clinic, Zurich, Switzerland, 4Center of Experimental Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, 5Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland

    Background/Purpose: The AAA-ATPase valosin containing protein (p97) and histone deacetylase 6 (HDAC6) interact with each other and are implicated in the degradation of ubiquitin-labelled proteins.…
  • Abstract Number: 1616 • 2015 ACR/ARHP Annual Meeting

    Identification of Genes Regulating TRAIL-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-like Synoviocytes (RA FLS)

    Rachel Audo1,2, Bernard Combe3,4, Michael Hahne5 and Jacques Morel6, 1Rheumatology, Teaching Hospital of Lapeyronie, Montpellier, France, 2IGMM, CNRS UMR5535, Montpellier, Montpellier, France, 3Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 4Montpellier University, Montpellier, France, 5IGMM-CNRS UMR5535, Montpellier, France, 6Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France

    Background/Purpose: We previously described that sensitivity to TRAIL-induced apoptosis varied in rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) from one patient to another, and was inversly correlated…
  • « Previous Page
  • 1
  • …
  • 174
  • 175
  • 176
  • 177
  • 178
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology